In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA

Journal of Infectious Diseases

Volumn 191, Issue 10, 2005, Pages 1686-1696

  Mallon, Patrick W G ^a,b,c   Unemori, Patrick ^a,c,e   Sedwell, Rebecca ^a,c   Morey, Adrienne ^b   Rafferty, Martina ^b   Williams, Kenneth ^b   Chisholm, Donald ^d   Samaras, Katherine ^d   Emery, Sean ^a   Kelleher, Anthony ^a,b,c   Cooper, David A ^a,b,c   Carr, Andrew ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Centre for Immunology   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LIPID METABOLISM; LIPOATROPHY; MALE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL GENETICS; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA TRANSCRIPTION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; AGED; BODY COMPOSITION; DNA, MITOCHONDRIAL; FEMALE; GENE EXPRESSION; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; UP-REGULATION;

EID: 20844435624     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/429697     Document Type: Article

References (37)

1. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
3. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 2003; 17:971-9.
4. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-51.
5. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfuction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-85.
6. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-32.
7. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-38.
8. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357:1412-4.
9. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998; 351:871-5.
10. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
11. an der Valk M, Gisolf EH, Wit FWNM, Japour A, Weverling GJ, Danner SA, on behalf of the Promethus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15:847-55.
12. Dowell P, Flexner C, Kwiterovich P, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275:41325-32.
13. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-31.
14. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-62.
15. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20:1868-76.
16. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24 (Suppl 4):78-90.
17. Spiegelman BM, Puigserver P, Wu Z. Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 2000; 24:S8-10.
18. Enriquez JA, Fernandez-Silva P, Montoya J. Autonomous regulation in mammalian mitochondrial DNA transcription. Biol Chem 1999; 380:737-47.
19. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000; 106:847-56.
20. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-22.
21. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-22.
22. Barrientos A, Barros MH, Valnot I, Rotig A, Rustin P, Tzagoloff A. Cytochrome oxidase in health and disease. Gene 2002; 286:53-63.
23. Martin I, Vinas O, Mampel T, Iglesias R, Villarroya F. Effects of cold environment on mitochondrial genome expression in the rat: evidence for a tissue-specific increase in the liver, independent of changes in mitochondrial gene abundance. Biochem J 1993; 296:231-4.
24. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-38.
25. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7:41-7.
26. Zechner R, Strauss J, Frank S, et al. The role of lipoprotein lipase in adipose tissue development and metabolism. Int J Obes Relat Metab Disord 2000; 24(Suppl 4):S53-6.
27. Williams RS, Salmons S, Newsholme EA, Kaufman RE, Mellor J. Regulation of nuclear and mitochondrial gene expression by contractile activity in skeletal muscle. J Biol Chem 1986; 261:376-80.
28. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16:513-8.
29. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70:497-505.
30. Moraes CT, Kenyon L, Hao H. Mechanisms of human mitochondrial DNA maintenance: the determining role of primary sequence and length over function. Mol Biol Cell 1999; 10:3345-56.
31. Davis AF, Ropp PA, Clayton DA, Copeland WC. Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication. Nucleic Acids Res 1996; 24:2753-9.
32. Liao X, Butlow RA. RTG1 and RTG2: two yeast genes required for a novel path of communication from mitochondria to the nucleus. Cell 1993; 72:61-71.
33. Considine RV. Regulation of leptin production. Rev Endocr Metab Disord 2001; 2:357-63.
34. Levy JR, Gyarmati J, Lesko JM, Adler RA, Stevens W. Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. Am J Physiol Endocrinol Metab 2000; 278:E892-901.
35. Liang J-S, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidaemia. Nature Medicine 2001; 7:1-5.
36. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51:3163-9.
37. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098-105.